Compare Campbell Soup Co. (CPB) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Zoetis Inc — how do they compare? Campbell Soup Co. trades at $22.65 (market cap $6.78B), while Zoetis Inc trades at $72.81 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 4.6× Campbell Soup Co.'s market cap, and Campbell Soup Co. pays the higher dividend (6.87%). Which is the better fit depends on your goals.
| CPB | ZTS | |
|---|---|---|
Market Cap | $6.78B | $31.14B |
Sector | Consumer Staples | Health |
52-Week High | $34.03 | $156.76 |
52-Week Low | $20.00 | $71.91 |
Enterprise Value | $13.38B | $38.70B |
Dividend Yield | 6.87% | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's (CPB) trades at $22.56, up 0.6% with bullish technical signals and mixed fundamentals. The stock shows strong valuation metrics with P/E of 11.1 and P/S of 0.7, while recent earnings beat expectations in Q1 2026. Revenue growth remains modest at $10.3B in 2025, though net margins compressed to 5.9%. Technical indicators suggest bullish momentum with support at $22 and resistance at $23.
CPB offers a compelling 7% dividend yield supported by stable cash flows, but faces margin pressure and analyst skepticism with only 3% buy ratings. The company's cost-saving initiatives and new product launches provide potential upside, though competitive pressures and consumer spending trends remain key risks for sustained growth.
Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.
The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
